Alnylam Pharmaceuticals (ALNY) Interest Expenses (2011 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Interest Expenses came in at $82.1 million in Q2 2026, up 33.51% YoY from $61.5 million in Q2 2025, and up 18.42% on a QoQ basis from $69.3 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Interest Expenses (2011 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 14 years of Interest Expenses data on file, last reported at $82.1 million in Q2 2026.
- Quarterly Interest Expenses rose 33.51% year-over-year to $82.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $195.8 million (down 3.88% YoY) and the FY2025 annual result came in at $252.6 million, down 90.94% from the prior year.
- Interest Expenses climbed to $82.1 million in Q2 2026, from $69.3 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $82.1 million in Q2 2026 to a low of $100000.0 in Q4 2025.
- A 5-year average of $41.4 million and a median of $37.1 million in 2024 frame the typical range for Interest Expenses.
- The widest YoY moves for Interest Expenses: up 95.53% in 2025, down 99.74% in 2025.
- Tracing ALNY's Interest Expenses over 5 years: stood at $29.9 million in 2022, then grew by 4.76% to $31.3 million in 2023, then advanced by 24.36% to $39.0 million in 2024, then slumped by 99.74% to $100000.0 in 2025, then soared by 81951.0% to $82.1 million in 2026.
- The last three Interest Expenses figures came in at $82.1 million (Q2 2026), $69.3 million (Q1 2026), and $100000.0 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 6.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 82.05 Mn |
| Jun 30, 2026 | 82.05 Mn |
| Mar 31, 2026 | 69.29 Mn |
| Mar 31, 2026 | 69.29 Mn |
| Dec 31, 2025 | 100,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Sep 30, 2025 | 44.40 Mn |
| Sep 30, 2025 | 44.40 Mn |
| Jun 30, 2025 | 40.25 Mn |
| Jun 30, 2025 | 40.25 Mn |
| Mar 31, 2025 | 68.93 Mn |
| Mar 31, 2025 | 68.93 Mn |
| Dec 31, 2024 | 12.33 Mn |
| Dec 31, 2024 | 12.33 Mn |
| Sep 30, 2024 | 34.38 Mn |
| Sep 30, 2024 | 34.38 Mn |
| Jun 30, 2024 | 33.26 Mn |
| Jun 30, 2024 | 33.26 Mn |
| Mar 31, 2024 | 35.25 Mn |
| Mar 31, 2024 | 35.25 Mn |